683 Capital Management’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

683 Capital Management’s Portfolio LKFT Stock Details LKFT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-110,100	Closed	-$2.77M	–	141
2025 Q1	$2.77M	Buy	110,100 +40,100	+57%	+$1.01M	0.19%	99
2024 Q4	$1.93M	Hold	70,000	–	–	0.12%	94
2024 Q3	$2.02M	Hold	70,000	–	–	0.15%	91
2024 Q2	$1.73M	Buy	70,000 +12,000	+21%	+$341K	0.13%	93
2024 Q1	$1.87M	Hold	58,000	–	–	0.14%	81
2023 Q4	$2.36M	Hold	58,000	–	–	0.19%	75
2023 Q3	$2M	Hold	58,000	–	–	0.16%	85
2023 Q2	$2.36M	Sell	58,000 -35,971	-38%	-$1.47M	0.17%	93
2023 Q1	$3.63M	Sell	93,971 -7,800	-8%	-$321K	0.27%	93
2022 Q4	$4.52M	Sell	101,771 -21,000	-17%	-$884K	0.38%	66
2022 Q3	$5.24M	Sell	122,771 -13,421	-10%	-$688K	0.4%	62
2022 Q2	$7.6M	Sell	136,192 -349,808	-72%	-$20.7M	0.54%	58
2022 Q1	$30.1M	Sell	486,000 -419,121	-46%	-$25.7M	1.61%	10
2021 Q4	$49.9M	Buy	905,121 +203,700	+29%	+$10.6M	1.84%	11
2021 Q3	$36.9M	Buy	701,421 +668,098	+2,005%	+$39.7M	1.44%	17
2021 Q2	$2.3M	Buy	+33,323	New	+$2.54M	0.08%	119

Other funds holding LKFT

Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

SBH

Segall Bryant & Hamill Chicago, Illinois $6.98B AUM 34.78% 1-Year Est. Return

DCM

DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

683 Capital Management's LKFT Position: Q2 2025 in Review

683 Capital Management sold out of Lakefront Biotherapeutics American Depositary Shares (LKFT) in Q2 2025, closing a stake of 110,100 shares — an estimated $2.77M sold.

683 Capital Management first reported a position in LKFT in Q2 2021 and held it in 16 quarters. The position peaked at $49.9M in Q4 2021. 85 funds tracked by Wall St. Rank hold LKFT as of Q2 2025.

683 Capital Management reported no remaining Lakefront Biotherapeutics American Depositary Shares position as of Q2 2025 after selling out during the quarter.
683 Capital Management sold 110,100 Lakefront Biotherapeutics American Depositary Shares shares in Q2 2025, an estimated $2.77M.
683 Capital Management first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q2 2021 and held it in 16 quarters.
683 Capital Management's Lakefront Biotherapeutics American Depositary Shares position peaked at $49.9M in Q4 2021.
85 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q2 2025.

Based on 683 Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.